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CANCER THERAPEUTICS
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism Piro Lito, 1 * Martha Solomon, 2 Lian-Sheng Li, 3 Rasmus Hansen, 3 Neal Rosen 1,2 * It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled. Consequently, drugs targeting the inactive or guanosine 5´-diphosphate-bound conformation are not expected to be effective. We describe a mechanism that enables such drugs to inhibit KRAS G12C signaling and cancer cell growth. Inhibition requires intact GTPase activity and occurs because drug-bound KRAS G12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state. Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug. Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRAS G12C inhibition, whereas its potentiation had the opposite effect. These findings reveal that KRAS G12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRAS G12C -driven cancers.
W ild-type RAS guanosine triphosphatases (GTPases) cycle between an active, guanosine 5´-triphosphate (GTP)-bound, and an inactive, guanosine 5´-diphosphate (GDP)-bound, state (1, 2) . This is mediated by nucleotide exchange factors, which catalyze the exchange of GDP for GTP, and GTPaseactivating proteins, which potentiate a weak intrinsic GTPase activity (3). Cancer-causing mutations impair the GTPase activity of RAS, causing it to accumulate in the activated state (4-6). Despite the prevalence of these mutations, no therapies that directly target this oncoprotein are currently available in the clinic (7) (8) (9) . A recently identified binding pocket in KRAS G12C (10) now enables the discovery of compounds that potently inhibit KRAS-GTP or effector signaling by this mutant.
Here we characterize a novel compound, ARS853, designed to bind KRAS G12C with high affinity (11) . The structures of ARS853 and previously reported (10) compounds (cmpds) 6 and 12 are shown in fig. S1A . Treatment of KRAS G12C -mutant lung cancer cells with ARS853 reduced the level of GTP-bound KRAS by more than 95% (Fig. 1A, 10 mΜ) . This caused decreased phosphorylation of CRAF, ERK (extracellular signalregulated kinase), and AKT. In contrast, even at the highest concentration tested, cmpd 6 or 12 had only a minimal effect on pCRAF and pERK, without affecting KRAS-GTP levels ( Fig. 1A and  fig. S1B ). ARS853 inhibited proliferation with an inhibitory concentration 50% (IC 50 ) of 2.5 mM, which was similar to its IC 50 for target inhibition (Fig. 1, A and B) . ARS853 (10 mM) inhibited effector signaling (Fig. 1C and fig. S1C ) and cell proliferation ( Fig. 1D and fig. S2 ) to varying degrees in six KRAS G12C mutant lung cancer cell lines, but not in non-KRAS G12C models (Fig. 1E  and fig. S1 , C and D). Similarly, it completely suppressed the effects of exogenous KRAS G12C expression on KRAS-GTP levels, KRAS-BRAF interaction, and ERK signaling ( fig. S1E ). Inhibitor treatment also induced apoptosis in four KRAS G12C mutant cell lines (Fig. 1, F to H) . Thus, ARS853 selectively reduces KRAS-GTP levels and RAS-effector signaling in KRAS G12C -mutant cells, while inhibiting their proliferation and inducing cell death.
In contrast to the rapid inhibition of signaling by kinase inhibitors, inhibition of KRAS G12C by ARS853 occurred slowly ( Fig. 2A and fig. S3 ). In some cell lines, maximal inhibition of KRAS-GTP occurred in 6 hours; in others, in 48 to 72 hours. To understand this phenomenon, we examined the mechanism of KRAS G12C inhibition in more detail. To determine whether ARS853 binds to the active or the inactive conformation of KRAS
G12C
, we used differential scanning fluorimetry, which assays ligand-induced changes in protein thermal stability (12) . Recombinant KRAS G12C was loaded with either GTPgS or GDP ( fig. S4A ) and then incubated with ARS853. Samples were incubated at increasing temperatures in the presence of a fluorescent dye that binds to hydrophobic surfaces exposed during thermal denaturation. ARS853 increased the amplitude of the thermal denaturation curve of KRAS G12C loaded with GDP but not with GTPgS ( Fig. 2B and fig. S4B ). ARS853 did not alter the denaturation curve of GDP-loaded KRAS WT ( fig. S4C ). These data suggest that ARS853 preferentially interacts with inactive, or GDP-bound, KRAS G12C . KRAS mutants are thought to exist in a "constitutively" active (GTP-bound) state in cancer cells (13) . Thus, inhibition of KRAS-GTP levels by a drug that preferentially interacts with GDPbound mutant KRAS is puzzling. Codon 12 mutations disable the activation of RAS GTPase by GTPase-activating proteins (14) (15) (16) . It is possible, however, that the basal GTPase activity of KRAS G12C is sufficient to enable nucleotide cycling in cancer cells. Consequently, we hypothesized that binding of the inhibitor to KRAS G12C traps it in an inactive (GDP-bound) conformation by reducing its susceptibility to exchange, which then results in the observed time-dependent reduction in cellular KRAS-GTP levels. For this to be the case, (i) inhibition by the drug should require KRAS G12C GTPase activity.
(ii) If KRAS G12C GTPase activity is constant, the rate of RAS inhibition by the drug should depend on exchange factor activity. (iii) Regulating exchange factor activity should affect drug potency and the kinetics of inhibition.
We tested this hypothesis by using mutations that occur in cancer patients and affect the guanine nucleotide cycle of RAS (Fig. 3A and fig.  S5A ). A59G is a "transition state" mutant that abrogates GTPase activity (17, 18) . When assayed for their GTPase activity (Fig. 3B) ( Fig. 3C and fig. S5B ). The crystal structure of HRAS A59G shows that Q61, a critical residue for GTP hydrolysis, is displaced in this mutant ( fig.  S5C ). Q61L impairs in vitro GTP hydrolysis by HRAS (19) , and, when expressed in HEK293 cells, KRAS G12C/Q61L was less sensitive to ARS853 than KRAS G12C ( fig. S5D ). Y64A both reduces RAS GTPase activity and impairs the interaction of HRAS with the active site of the guanine nucleotide exchange factor (GEF) SOS (18, 20, 21) (fig. S6 , A to C). As expected, ARS853 caused only minimal inhibition of GTP-bound KRAS G12C/Y64A or signaling driven by this mutant (fig. S6D) . Thus, KRAS G12C GTPase activity is required for its inhibition by ARS853.
The percentage of KRAS G12C bound to ARS853 in cells was evaluated by mass spectrometry (Fig. 3D, dotted line) . GTPase-impairing mutations A59G or Y64A diminished the cellular interaction of ARS853 with KRAS G12C by~75 and 50%, respectively. This effect was inversely proportional to their effect on KRAS G12C -GTP inhibition (Fig. 3D, solid line) , supporting the conclusions that ARS853 interacts preferentially with GDP-bound KRAS G12C in cells and that GTPase activity is required for the drug to bind and inhibit KRAS G12C .
ARS853 reduced the interaction of KRAS

G12C
with the catalytic subunit of SOS (Fig. 3E) and attenuated SOS-mediated nucleotide exchange by KRAS G12C (fig. S6E ). These findings suggest that ARS853 traps KRAS G12C in a GDP-bound conformation by lowering its affinity for nucleotide exchange factors. It is therefore possible that nucleotide exchange activity modulates the effect of ARS853. We tested whether RAS mutations that affect nucleotide exchange alter the sensitivity of KRAS G12C to ARS853 (Fig. 3F) . Y40A, N116H, and A146V increase, whereas Y32S decreases, nucleotide exchange (22) (23) (24) . Mutations that increase exchange attenuated the effect of ARS853 on KRAS G12C -GTP, whereas Y32S caused a small augmentation of its effect (Fig. 3, G and  H, and fig. S6, F and G) . These data imply that potentiation of nucleotide exchange reduces sensitivity to ARS853, by lowering the levels of GDP-bound KRAS G12C available for drug binding. If the inhibitor works by the trapping mechanism suggested by these data (Fig. 4A) , then cellular parameters regulating nucleotide exchange ought to modulate the inhibition of KRAS G12C . Exposure to epidermal growth factor (EGF), an activator of SOS (25) , delayed the inhibition of KRAS G12C by ARS853 by several hours compared to inhibition in serum-free medium (Fig. 4B and  fig. S7A ). Treatment with an EGF receptor (EGFR) inhibitor ( fig. S7 , B and C) or SOS-specific small interfering RNAs ( fig. S7D ) had the opposite effect. We determined if EGFR signaling affects the inhibition of the mutant KRAS G12C allele, by expressing hemagglutinin (HA)-tagged KRAS G12C in EGFR-mutant PC9 cells, in which nucleotide exchange depends on EGFR (26, 27) . The specific effect on the mutant allele was determined by pulling down active KRAS and then immunoblotting for HA-tagged KRAS G12C . ARS853 inhibited GTP-bound KRAS G12C more potently in the presence of gefitinib, as compared to its absence ( fig. S7E) detected by the RBD:PD is low because the Y40 mutation impairs the interaction of RAS with RAF (33) . See also the effects of N116H and A146V mutations, which increase nucleotide exchange without affecting RAS-RAF interaction ( fig. S6G ).
enhanced the suppression of KRAS-GTP levels by ARS853 in both KRAS G12C homozygous and heterozygous cells (fig. S7F ). Receptor tyrosine kinase (RTK) signaling and nucleotide exchange are also subject to feedback inhibition by ERK or AKT (28) . Mitogen-activated protein kinase kinase (MEK) or AKT inhibitors relieve this feedback and activated RTK signaling (29, 30) . Inhibiting these pathways also attenuated the inhibitory effect of ARS853 ( fig. S7, G and H) . Taken together, these findings show that RTKmediated nucleotide exchange regulates the kinetics and potency of KRAS G12C inhibition in cancer cells.
The above results also suggest that pharmacologic inhibition of the exchange reaction, as achieved, for example, with inhibitors of RTK signaling, ought to potentiate the antiproliferative effect of KRAS G12C inhibitors. To test this hypothesis, we evaluated the effects of 11 inhibitors targeting RTKs, or their downstream signaling pathways, in KRAS G12C -mutant cell lines.
In agreement with our model, inhibiting the tyrosine kinase activities of MET, SRC, or FGFR (fibroblast growth factor receptor) enhanced growth inhibition by ARS853 in H1972 and H2030 cells, whereas MEK, ERK, phosphatidylinositol 3-kinase (PI3K), or AKT inhibitor treatment did not have a significant effect (Fig. 4, C  and D) . In H2122 and Calu-1 cells, the effect of ARS853 was potentiated by concurrent inhibition of EGFR (Fig. 4D) . Inhibition of EGFR also enhanced the induction of caspase activity by ARS853 ( fig. S7I ). These findings support another report showing that EGFR is required for KRASdriven cancer formation (31) and suggest that the RTKs responsible for modulating the timing of KRAS G12C inhibition in lung cancer vary from tumor to tumor. They also provide a rationale for selecting optimal combination treatments to achieve maximal KRAS G12C inhibition in patients.
We thus report an inhibitor that suppresses KRAS G12C signaling and tumor cell growth by binding to the GDP-bound form of the protein. This reduces the levels of KRAS G12C -GTP, because the protein retains GTPase activity and undergoes nucleotide cycling in cells. Some RAS mutants have low levels of basal GTPase activity in vitro; yet, perhaps owing to an inability to directly test such activity in vivo, these oncoproteins are assumed to be constitutively GTPbound in cancer cells. The data presented here, however, indicate that inhibition by ARS853 requires GTPase activity and that nucleotide exchange activity is inversely related to the kinetics and/or magnitude of inhibition. The model suggests that the RAS inhibitor and exchange factors compete for binding to KRAS G12C -GDP. Drug-bound KRAS G12C -GDP is not susceptible to exchange and exits the cycle, thus lowering the levels of KRAS G12C -GTP. This model also predicts that genetic alterations that completely disable KRAS G12C GTPase activity, or those that activate nucleotide exchange function, will confer resistance to this class of drugs. Careful selection of combination therapies may in turn prevent or delay the emergence of resistance by enabling a more potent inhibition of KRAS G12C . The mechanism of action elucidated here establishes a basis for such combination therapies. Inhibitors of receptors dominantly responsible for activation of RAS nucleotide exchange are predicted to enhance activity, whereas inhibitors of downstream pathways that reactivate these receptors are likely to blunt inhibition of mutant KRAS. KRAS G12C mutations occur in 16% of lung adenocarcinomas (32) , making them one of the most frequent activating genetic alterations in lung cancer, a disease responsible for approximately 1.6 million annual deaths worldwide. No effective inhibitor of mutant KRAS has yet been developed for use in the clinic. Our results suggest that KRAS G12C allele-specific inhibitors, such as the one described here, merit investigation as potential therapeutics for KRAS G12C -lung cancers.
